Nsiah Irene, Campbell Patrick J, Parikh Megha A, Hines Lisa E, Pickering Matthew, Nau David P
Department of Pharmacy Administration, The University of Mississippi, Oxford, MS.
Pharmacy Quality Alliance, Alexandria, VA.
Clin Diabetes. 2024 Spring;42(2):257-265. doi: 10.2337/cd23-0016. Epub 2023 Dec 19.
This study examined the association between persistence to basal insulin and clinical and economic health outcomes. The question of whether a persistence measure for basal insulin could be leveraged in quality measurement was also explored. Using the IBM-Truven MarketScan Commercial and Medicare Supplemental Databases from 1 January 2011 to 31 December 2015, a total of 14,126 subjects were included in the analyses, wherein 9,898 (70.1%) were categorized as persistent with basal insulin therapy. Basal insulin persistence was associated with lower A1C, fewer hospitalizations and emergency department visits, and lower health care expenditures. Quality measures based on prescription drug claims for basal insulin are feasible and should be considered for guiding quality improvement efforts.
本研究考察了基础胰岛素治疗的持续性与临床及经济健康结局之间的关联。同时还探讨了基础胰岛素的持续性指标能否用于质量评估这一问题。利用2011年1月1日至2015年12月31日的IBM-Truven市场扫描商业数据库和医疗保险补充数据库，共有14126名受试者纳入分析，其中9898名（70.1%）被归类为持续接受基础胰岛素治疗。基础胰岛素治疗的持续性与较低的糖化血红蛋白、较少的住院次数和急诊就诊次数以及较低的医疗保健支出相关。基于基础胰岛素处方药报销申请的质量指标是可行的，应考虑用于指导质量改进工作。
